• 1
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de SG et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:e46215.
  • 2
    Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. Am Heart J 2006;151:14652.
  • 3
    Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:33843.
  • 4
    McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006;98:5K13K.
  • 5
    Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:225964.
  • 6
    Ali T, Khan I, Simpson W, Prescott G, Townend J, Smith W et al. Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 2007;18:12928.
  • 7
    Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:9306.
  • 8
    Scheller B. How to protect from contrast media-induced nephropathy? Clin Res Cardiol 2007;96:1259.
  • 9
    McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:36875.
  • 10
    Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Interv 2001;52:40916.
  • 11
    Stacul F, Van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011;21:252741.
  • 12
    Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989;320:1439.
  • 13
    Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989;320:14953.
  • 14
    Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005;172:146171.
  • 15
    Reinecke H, Trey T, Matzkies F, Fobker M, Breithardt G, Schaefer RM. Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int 2003;63:696701.
  • 16
    Thomsen HS, Morcos SK. Management of acute adverse reactions to contrast media. Eur Radiol 2004;14:47681.
  • 17
    Weisbord SD, Palevsky PM. Contrast-induced acute kidney injury: short- and long-term implications. Semin Nephrol 2011;31:3009.
  • 18
    From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc 2008;83:1095100.
  • 19
    Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. Isr Med Assoc J 2009;11:4604.
  • 20
    Goldenberg I, Chonchol M, Guetta V. Reversible acute kidney injury following contrast exposure and the risk of long-term mortality. Am J Nephrol 2009;29:13644.
  • 21
    Morcos SK. Prevention of contrast media nephrotoxicity–the story so far. Clin Radiol 2004;59:3819.
  • 22
    McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med 2003;4(Suppl. 5):S39.
  • 23
    Morcos SK. Contrast nephrotoxicity and iso-osmolar contrast agents: implications of nephric. Clin Radiol 2004;59:297.
  • 24
    Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 2006;100:S513.
  • 25
    Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. Catheter Cardiovasc Interv 2010;75(Suppl. 1):S1520.
  • 26
    Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004;183:167389.
  • 27
    Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004;79:2119.
  • 28
    Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235:8439.
  • 29
    Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008;49:64657.
  • 30
    Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J 2012;33:200715.
  • 31
    McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv 2006;67:33543.
  • 32
    Almen T. Visipaque–a step forward. A historical review. Acta Radiol Suppl 1995;399:218.
  • 33
    Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De NL. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:14518.
  • 34
    Gupta R, Gurm HS, Bhatt DL, Chew DP, Ellis SG. Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv 2005;64:4428.
  • 35
    Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14K20K.
  • 36
    Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol 2010;6:67988.
  • 37
    Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008;21:7485.
  • 38
    Deray G, Baumelou B, Martinez F, Brillet G, Jacobs C. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and non ischemic canine kidney. Clin Nephrol 1991;36:936.
  • 39
    Talner LB, Davidson AJ. Renal hemodynamic effects of contrast media. Invest Radiol 1968;3:3107.
  • 40
    Humes HD, Hunt DA, White MD. Direct toxic effect of the radiocontrast agent diatrizoate on renal proximal tubule cells. Am J Physiol 1987;252:F24655.
  • 41
    Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med 1987;110:40611.
  • 42
    Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992;41:140815.
  • 43
    Baars T, Kleinbongard P, Bose D, Konorza T, Mohlenkamp S, Hippler J et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. Basic Res Cardiol 2012;107:303.
  • 44
    Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:25461.
  • 45
    Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. Crit Care Med 2006;34:20608.
  • 46
    Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005;289:F42030.
  • 47
    Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004;93:15159.
  • 48
    Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M et al. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003;15:1822.
  • 49
    Alamartine E, Phayphet M, Thibaudin D, Barral FG, Veyret C. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. Eur J Intern Med 2003;14:42631.
  • 50
    Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:68591.
  • 51
    Evenepoel P. Acute toxic renal failure. Best Pract Res Clin Anaesthesiol 2004;18:3752.
  • 52
    Wickenbrock I, Perings C, Maagh P, Quack I, van BM, Prull MW et al. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009;98:76572.
  • 53
    Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De BD et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006;10:R73.
  • 54
    Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
  • 55
    Kellum JA. KDIGO clinical practice guideline for acute kidney injury. In: 2, 1; doi:10.1038/kisup.2012.1 ed, 2012.
  • 56
    Schiffl H, Lang SM. Update on biomarkers of acute kidney injury: moving closer to clinical impact? Mol Diagn Ther 2012;16:199207.
  • 57
    Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:150517.
  • 58
    Schinstock CA, Semret MH, Wagner SJ, Borland TM, Bryant SC, Kashani KB et al. Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrol Dial Transplant 2012; [Epub ahead of print].
  • 59
    Buelow MW, Dall A, Regner K, Weinberg C, Bartz PJ, Sowinski J et al. Urinary interleukin-18 and urinary neutrophil gelatinase-associated lipocalin predict acute kidney injury following pulmonary valve replacement prior to serum creatinine. Congenit Heart Dis 2012;7:4417.
  • 60
    Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:101224.
  • 61
    Heller F, Frischmann S, Grunbaum M, Zidek W, Westhoff TH. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol 2011;6:234755.
  • 62
    Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol 2008;51:8990.
  • 63
    Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:10646.
  • 64
    Hafiz AM, Jan MF, Mori N, Shaikh F, Wallach J, Bajwa T et al. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies. Catheter Cardiovasc Interv 2012;79:92937.
  • 65
    Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:32936.
  • 66
    Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:6471.
  • 67
    Atkins JL. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 1986;44:704.
  • 68
    Adolph E, Holdt-Lehmann B, Chatterjee T, Paschka S, Prott A, Schneider H et al. Renal insufficiency following radiocontrast exposure trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 2008;19:4139.
  • 69
    Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008;52:599604.
  • 70
    Tamura A, Goto Y, Miyamoto K, Naono S, Kawano Y, Kotoku M et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol 2009;104:9215.
  • 71
    Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008;300:103846.
  • 72
    Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 2009;7:23.
  • 73
    Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:61727.
  • 74
    Jang JS, Jin HY, Seo JS, Yang TH, Kim DK, Kim TH et al. Sodium bicarbonate therapy for the prevention of contrast-induced acute kidney injury. Circ J 2012;76:225565.
  • 75
    Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant 2010;25:74758.
  • 76
    Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al SA et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004;148:4229.
  • 77
    Tanaka A, Suzuki Y, Suzuki N, Hirai T, Yasuda N, Miki K et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med 2011;50:6737.
  • 78
    Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 2004;25:2128.
  • 79
    Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:26372.
  • 80
    Munzel T, Keaney JF Jr. Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 2001;104:15714.
  • 81
    Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999;51:5216.
  • 82
    Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL. [The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography]. Anadolu Kardiyol Derg 2003;3:98103.
  • 83
    Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006;104:c207.
  • 84
    Maeder M, Klein M, Fehr T, Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 2004;44:176371.
  • 85
    Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von BC et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:21803.
  • 86
    Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005;118:8439.
  • 87
    Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:1718.
  • 88
    Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:115563.
  • 89
    Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 2007;50:40918.
  • 90
    Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:8939.
  • 91
    Walsh SR, Boyle JR, Tang TY, Sadat U, Cooper DG, Lapsley M et al. Remote ischemic preconditioning for renal and cardiac protection during endovascular aneurysm repair: a randomized controlled trial. J Endovasc Ther 2009;16:6809.
  • 92
    Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007;116:I98105.
  • 93
    Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J et al. Remote ischemic preconditioning reduces myocardial injury after coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 2010;105:65764.
  • 94
    Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E et al. Ischemic preconditioning for prevention of contrast-medium-induced nephropathy: randomized pilot renpro-trial (renal protection trial). Circulation 2012;52:230.